title: Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.
abstract: The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis, with promising results. However, the use of such therapies has been associated with an increased risk of developing other autoimmune diseases. In addition, the use of anti-TNF agents can cause pulmonary complications, such as reactivation of mycobacterial and fungal infections, as well as sarcoidosis and other interstitial lung diseases (ILDs). There is evidence of an association between ILD and the use of anti-TNF agents, etanercept and infliximab in particular. Adalimumab is the newest drug in this class, and some authors have suggested that its use might induce or exacerbate preexisting ILDs. In this study, we report the first case of acute ILD secondary to the use of adalimumab in Brazil, in a patient with rheumatoid arthritis and without a history of ILD.
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Collaborating Physician, Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: Olívia Meira
authors.initials: OM
authors.lastname: Dias
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Collaborating Physician, Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: Daniel Antunes Silva
authors.initials: DA
authors.lastname: Pereira
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Attending Physician. Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: Bruno Guedes
authors.initials: BG
authors.lastname: Baldi
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Attending Physician. Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: André Nathan
authors.initials: AN
authors.lastname: Costa
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Attending Physician. Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: Rodrigo Abensur
authors.initials: RA
authors.lastname: Athanazio
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Associate Professor. Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas , São Paulo, Brazil.
authors.forename: Ronaldo Adib
authors.initials: RA
authors.lastname: Kairalla
authors.affiliation: University of São Paulo, School of Medicine, Hospital das Clínicas, São Paulo, Brazil, Full Professor. Department of Pulmonology, Heart Institute, University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.
authors.forename: Carlos Roberto Ribeiro
authors.initials: CR
authors.lastname: Carvalho
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008875:Middle Aged
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab